Komori
Kewpie (2809) · InitiativeFirst stated

Commercialization of a Proposal to Reduce Cancer Risk Through MicroRNA

First written in FY2021. . Latest entry: FY2021.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Cancer Risk Assessment and Dietary Recommendations Using microRNAA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021First statedAnnual report

    「We aim to commercialize dietary proposals that use measurements of microRNA in the blood to assess future cancer risk and improve microRNA in order to reduce that risk. We are currently conducting joint research with Yokohama National University and Tokyo Medical University as part of a project operated by NEDO, the New Energy and Industrial Technology Development Organization, under its Technology Development Project for Next-Generation Artificial Intelligence That Evolves with Humans.」

    Research is being conducted with universities and an NEDO project to commercialize cancer-risk assessment using microRNA measurements and related dietary proposals.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kewpie yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.